Replies to post #239315 on Elite Pharmaceuticals Inc (ELTP)

[lasers]

$ELTP is the expert at Commercial pricing of their ANDAs and exactly why their ANDAs are growing increased revenues now at +$12 mil/yr.

While the Courts ruled in favor of TEVA's Oxycontin Generic in Feb 2016 it is not certain what Purdue is planning to do next, if anything.


http://www.reuters.com/article/us-oxycontin-ruling-idUSKCN0VA3GC

HEALTH NEWS | Mon Feb 1, 2016 | 8:18pm EST
U.S. appeals court ruling may clear barrier to generic OxyContin

TEVA has been currently selling their authorized NDA Generic ER Oxycontin since the Higher Court ruling.

A federal appeals court ruled Monday that four patents related to Purdue Pharma's painkiller OxyContin are invalid

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d574a71a-2fe0-4cb7-95be-0a3c32e4e92e

It is looking more like Purdue has accepted legal defeat and exactly why $ELTP is now ready to submit its own Oxycontin ADF ANDA!